Analysis Group Consultants Contribute to Award-Winning Research on Real-World Outcomes in Multiple Myeloma

November 20, 2025

Analysis Group researchers collaborated on a study recognized as the best abstract in myeloma at the 2025 Lymphoma, Leukemia & Myeloma (LLM) Congress. This work was presented as a podium session titled Real-world Description of Non-ICANS Neurologic Events Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel Using Two Large US Databases.

Vice President Bruno Émond and Manager Jessica Maitland were part of a team that analyzed real-world data (RWD) on the occurrence of non-immune effector cell-associated neurotoxicity syndrome (non-ICANS) neurological events in patients who received ciltacabtagene autoleucel (cilta-cel), a CAR-T cell therapy used to treat relapsed or refractory multiple myeloma. Two retrospective databases were used to analyze patients who received cilta-cel in clinical practice to better understand these events outside of controlled clinical trials.

This research is the first to use RWD to evaluate non-ICANS neurological events in patients treated with cilta-cel, across multiple databases. Dr. Zaina P. Qureshi of Johnson & Johnson presented the study during the “Advancing Treatments in Myeloma” session at the Congress.

Further details on the presentation are available on the LLM Congress 2025 website.